@brunetteduoblog's hormone therapy claims, fact-checked

What does this video actually claim?

Alexandra from @brunetteduoblog shares her post-surgery breast cancer treatment plan, saying she's cancer-free but will undergo radiation followed by hormone therapy. She outlines three specific medications: goserelin injections to shut off estrogen for 5-10 years, anastrozole pills to block remaining estrogen for 5-10 years, and Kisqali (ribociclib) to stop cancer cell growth for 3 years.

This represents standard adjuvant hormone therapy for hormone receptor-positive breast cancer. Her description is straightforward and medically accurate.

Does the science back up these treatments?

Yes, this combination has solid evidence behind it. The MONALEESA-7 trial (Tripathy et al., NEJM, 2018) showed that adding ribociclib to endocrine therapy improved progression-free survival by 13.1 months in premenopausal women with HR-positive metastatic breast cancer.

For early-stage disease, the monarchE trial (Johnston et al., NEJM, 2020) found that adding abemaciclib (another CDK4/6 inhibitor like Kisqali) reduced invasive disease recurrence by 25.3% at 2 years. Goserelin plus anastrozole forms the backbone of this approach.

The 5-10 year timeframes she mentions align with standard guidelines. The ATLAS trial showed tamoxifen benefits extended beyond 5 years, and similar principles apply to aromatase inhibitors like anastrozole.

What did she get right?

Alexandra nailed the basic mechanisms and timeline. Goserelin does shut down ovarian estrogen production by blocking GnRH receptors. Anastrozole blocks the aromatase enzyme that converts androgens to estrogen, achieving 97% estrogen suppression in postmenopausal women.

Kisqali (ribociclib) is a CDK4/6 inhibitor that blocks cancer cell division. Her 3-year duration matches current protocols, though some trials are exploring longer treatment periods.

She's also realistic about this being prevention rather than cure. That's medically accurate thinking.

What's missing from her explanation?

She doesn't mention side effects, which are substantial with this regimen. The MONALEESA-7 trial reported grade 3-4 neutropenia in 60% of ribociclib patients versus 4% on endocrine therapy alone.

Goserelin causes surgical menopause symptoms including hot flashes, bone loss, and mood changes. Long-term anastrozole increases fracture risk and joint pain.

She also doesn't explain that this appears to be treatment for early-stage disease based on her "prevention" framing, though the specific indication matters for prognosis and duration decisions.

What should you actually know?

This represents aggressive but evidence-based treatment for hormone-positive breast cancer. The combination of ovarian suppression, aromatase inhibition, and CDK4/6 inhibition can reduce recurrence risk by 30-40% in appropriate patients.

However, quality of life impacts are real. Many women struggle with the menopausal symptoms from goserelin, and ribociclib requires regular blood monitoring for liver function and QT prolongation.

Treatment decisions should balance efficacy with tolerability. Some patients may opt for shorter durations or different combinations based on their specific risk factors and preferences.